Preparation and Evaluation of A Recent Infectious Laryngotracheitis (ILT) Vaccine from A Local Field Isolate

Nada A. Fathy1, Abd El-Moneam M.M1, Ibrahim S2, Norhan Nagy Mohamed3, Amina A. Radwan4, Rafik Hamed Sayed5

1Department of Newcastle disease Vaccine Research, Veterinary Serum and Vaccines Research Institute (VSVRI), Agricultural Research Center (ARC), Abbassia, Cairo, Egypt.
2Department of Genetic Engineering, Veterinary Serum and Vaccines Research Institute (VSVRI), Agricultural Research Center (ARC), Abbassia, Cairo, Egypt.
3Central Laboratory for Evaluation of Veterinary Biologics (CLEVB), Agricultural Research Center (ARC), Abbassia, Cairo, Egypt.

*Corresponding Author, Nada A. Fathy, E-mail: nadadl@yahoo.com

ABSTRACT

Infectious laryngotracheitis (ILT) is a respiratory tract disease affecting chickens worldwide. The disease leads to severe production losses due to increased mortality, decreased egg production, and delayed body weight gain, causing enormous economic losses to the poultry industry. ILT is controlled through vaccination with live-modified attenuated vaccines of chicken embryo origin (CEO) and/or the tissue-culture origin (TCO). This study was conducted to develop Specific Pathogenic Free (SPF) egg-adapted live attenuated ILT vaccine from the field strain Fayoum_2018 isolated from broilers in Fayoum Province, Egypt in 2018. The isolate Fayoum_2018 with accession number (MN082684) was characterized molecularly as a TCO vaccine related strain. Measurement of immunity in vaccinated chicks employing the potency test revealed that chicks vaccinated with 0.5 ml of prepared ILT vaccine exhibited ELISA with 1905 antibody titer at 2nd week post-vaccination, which was considered an ILT adequate immune response and increased till reach 3497 antibody titer at 6th week post-vaccination. The current work revealed that Fayoum_2018 ILTV egg adapted live attenuated vaccine produced a satisfactory antibodies titer that was efficient in controlling the ILT field infection in Egypt.

Keywords: BVDV, CEO, ELISA, ILT, TCO, SPF.

INTRODUCTION

Infectious Laryngotracheitis (ILT) is an acute respiratory disease caused by the infectious Laryngotracheitis virus. This virus is a member of sub-family Alphaherpesvirinae (genus Iltovirus) which affects the upper respiratory tract of chickens (Davison, 2010). In 1925, ILT was firstly described by May and Tittsler 1925. After that, the vaccination of chicken was achieved through cloacal injection of birds with the virulent virus (Brandly and Bushnell, 1934). Noteworthy, this was the first effective vaccine developed for a major avian viral disease (Guy and García, 2008). ILT is controlled through vaccination with live-modified attenuated vaccines, the chicken embryo origin (CEO) vaccines and the tissue-culture origin (TCO) vaccines. Generally, CEO vaccines induce better protection than TCO vaccines (Andreasen et al., 1989).

The CEO vaccine revealed top protection by reducing clinical signs and viral replication (Palomino-Tapia et al., 2019). However, live attenuated ILT vaccines can create latently infected carrier chickens that become a source for the spread of the virus to non-vaccinated flocks. Therefore, it is recommended to use live attenuated ILT vaccines only in endemic areas (Shan-Chia Ou and Joseph Giambrone, 2012).

In the current study, an egg-adapted ILT live attenuated vaccine was prepared from our field strain Fayoum_2018, isolated from Fayoum province. It was molecularly characterized as a TCO vaccine related strain reported to be retained either by the back passage of an attenuated TCO vaccine strain in susceptible non-vaccinated birds or from genetic recombination of two different TCO vaccine strains (Nourhan et al., 2019).
MATERIALS AND METHODS

ILT field isolate

An Egyptian strain of virulent infectious laryngotracheitis virus (ILTV) named Fayoum_2018 with accession number (MN082684) was isolated from Fayoum province and characterized molecularly as a TCO vaccine related strain (Nourhan et al., 2019). For the preparation of a live attenuated ILT vaccine, an adaptation of the Fayoum_18 strain was conducted through several passages on the chorioallantoic membrane (CAM) of embryonated chicken eggs (ECE) inducing typical pock lesions on CAM. The period of the work from July 2019 till March 2020.

Virulent Challenge ILT virus

A local isolate of ILT virus was supplied by Reference Strain Department, Central Laboratory for Evaluation of Veterinary Biologics (CLEVB), Abbasia, Cairo, Egypt. It had a titer of 10^3.5 EID₅₀/ml and used for the challenge of experimentally vaccinated chicken.

Specific Pathogen Free (SPF) Chicken

A total of 100 susceptible 3-weeks-old SPF chicken were obtained from the SPF Egg Production Farm, Koum Oshein, El-Fayoum, Egypt used to monitor the egg adapted pathogenicity virus and for vaccine evaluation. These SPF chicken were divided into three groups as follows:

- Forty SPF chicken was used to test the pathogenicity of the egg propagated virus.
- Twenty SPF chicken was used for testing the safety of the prepared vaccine.
- Forty SPF chicken was used for assessment of the potency test.

Serum samples were collected from all birds weekly until six weeks post-vaccination and used to measure antibody levels by ELISA.

SPF embryonated chicken Egg (SPF-ECE)

SPF eggs were obtained from the SPF Egg Production Farm, Koum Oshein, El-Fayoum, Egypt used for virus propagation and titration.

Stabilizer

Lactalbumin sucrose stabilizer (5% lactalbumin hydrolysate and 2.5 % sucrose) was prepared according to the (OIE 2014) then added to the ILT virus as a stabilizer. This mixture was distributed in sterile neutral glass vials (2ml/vial) and lyophilized.

ILT virus propagation on CAM of SPF Eggs

ILT virus propagated and titrated on CAM of SPF Eggs. The virus isolate was inoculated onto CAM of SPF Egg for five successive passages. Virus propagation was performed following the procedure mentioned by (OIE, 2014). Briefly, tissue homogenates of the previously collected pooled samples were centrifuged and the supernatant was collected. Ten-fold serial dilutions of the CAMs homogenates into 12-days-old SPF-ECEs were inoculated in 5 SPF- ECEs for each dilution, separately. The inoculated and non-inoculated (i.e., negative control) eggs were incubated at 37°C.

Meanwhile, all were observed and candled for five days post-inoculation. Thereafter, all the inoculated eggs were opened, CAMs were cut to collect pock lesions areas before pooling and further passage of the virus in ECEs. The pock lesions were detected 5-days post-inoculation followed by titer calculation using the statistical method described by Reed and Muench (Reed and Muench, 1938).

Testing the pathogenicity of the egg adapted ILT virus in susceptible SPF chicken

The egg adapted virus was inoculated in 30 susceptible 3-weeks-old SPF chicken via the intra-tracheal route with 100 µl of 10^3.5 EID₅₀ of the isolated virus. Ten susceptible SPF chicken was used as control non-inoculated (Guy et al., 1990). Birds were scored for clinical signs for 2-10 days post-inoculation.

Evaluation of the egg adapted ILT vaccine (Quality control)

Sterility

Random samples of the lyophilized vaccine were inoculated separately into plates of nutrient agar, Sabouraud dextrose agar, thioglycollate medium and mycoplasma medium for bacterial contamination (Code of Federal Regulations USA, 2017). The lyophilized vaccine was also examined for the presence of extraneous viruses other than ILT.

Potency test

Infectivity of live ILT virus vaccine is tested by titration in ECEs as follow:

Ten-fold serial dilutions between 10⁻¹ and 10⁻⁷ of each passage (5 passages) were prepared from the vaccine in sterile PBS, pH 7.2 containing antibiotic. The dilutions between 10⁻⁴ and 10⁻⁷ were inoculated into 10-12 days-old SPF-ECEs via CAM (5 eggs/dilution, 0.2µl/egg). These eggs were incubated at 37°C for 7 days, underwent daily examination. Deaths of ECEs occurred during the first 24 hours were disregarded. Embryos died later were examined individually and those survive up to the seventh day of incubation were examined for ILTV lesions (pock like lesions on CAM or thickening of CAM). (OIE, 2014)

Immunogenicity

Twenty five SPF-chickens, three weeks old were vaccinated with 0.2 ml of the vaccine by intra-tracheal inoculation route. Besides, fifteen chickens of
the same age and source were maintained as controls. Serum samples were collected 14-days post-vaccination. After that, serum samples were collected every week until the sixth week to screen by ELISA. (OIE, 2014).

A serological assay using Enzyme-linked Immunosorbent assay test (ELISA)
ILT indirect ELISA test was applied using ID Screen ILT indirect kit from ID.vet® for the quantitative detection of ILT specific antibodies in chicken sera.

RESULTS

ILT virus propagation on SPF Egg
ILT virus propagated on CAM of SPF egg showed pock lesions characterized by the thick grey plaques typical for ILTV growth (Fig. 1).

![Fig. 1: Chorio-allantoic membranes showing pock lesions characteristic for ILT virus](image)

ILT virus titration
Table 1 illustrated that the virus titer reached 3.5 log10 EID50/ml at passage number 5.

<table>
<thead>
<tr>
<th>No of passage</th>
<th>Virus titer log10 EID50/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st passage</td>
<td>2.0</td>
</tr>
<tr>
<td>2nd passage</td>
<td>2.0</td>
</tr>
<tr>
<td>3rd passage</td>
<td>2.5</td>
</tr>
<tr>
<td>4th passage</td>
<td>3.0</td>
</tr>
<tr>
<td>5th passage</td>
<td>3.5</td>
</tr>
</tbody>
</table>

Pathogenicity test of the propagated virus
The pathogenicity of the ILT virus propagated on CAM of SPF eggs was conducted on susceptible SPF chicken. Table 2 shows that the 5th passage is a safe virus passage. Intra-tracheal pathogenicity index (ITPI) was calculated and expressed as means. Each bird’s clinical signs were reported daily for 14 days as follows: 0, normal; 1, respiratory signs; 3, death. Indices were determined by dividing the sum of the scores by the total number of chickens.

<table>
<thead>
<tr>
<th>Virus passage</th>
<th>No. of inoculated birds</th>
<th>No. of birds showing Morbidity post-vaccination</th>
<th>No. of birds showing mortality post-vaccination</th>
<th>ITPI*</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>10</td>
<td>6</td>
<td>4</td>
<td>0.4</td>
</tr>
<tr>
<td>3</td>
<td>10</td>
<td>6</td>
<td>4</td>
<td>0.4</td>
</tr>
<tr>
<td>4</td>
<td>10</td>
<td>3</td>
<td>1</td>
<td>0.1</td>
</tr>
<tr>
<td>5</td>
<td>10</td>
<td>0</td>
<td>0</td>
<td>0.0</td>
</tr>
</tbody>
</table>

* ITPI: Intra Tracheal Pathogenicity Index

ILT virus vaccine titer after lyophilization
This lyophilized vaccine was re-titrated in CAM of SPF eggs showing a titer of 10^3.0 EID50/ml.

Quality control of the prepared ILT vaccine
Sterility test
Bacterial and viral sterility of prepared vaccines proved it is free from bacterial and fungal contamination and extraneous viruses.

Safety test
On the inoculation of ILT vaccine in susceptible chicken with ten times of the recommended dose none of the vaccinated birds show undesirable symptoms refer to ILT, which proves that the produced vaccine was safe to be used in chicken.

Serological test
ELISA test
Table 3: Results of the ELISA test of sera collected from vaccinated and control chickens

<table>
<thead>
<tr>
<th>Weeks post-vaccination</th>
<th>ILT Vaccinated chickens</th>
<th>Control non-vaccinated chickens</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>1905</td>
<td>505</td>
</tr>
<tr>
<td>3</td>
<td>3009</td>
<td>507</td>
</tr>
<tr>
<td>4</td>
<td>3605</td>
<td>490</td>
</tr>
<tr>
<td>5</td>
<td>3547</td>
<td>488</td>
</tr>
<tr>
<td>6</td>
<td>3497</td>
<td>500</td>
</tr>
</tbody>
</table>
DISCUSSION

Worldwide, the control of viral diseases in poultry is regulated and relies upon vaccination and high biosecurity standards. There are two types of live-attenuated vaccines utilized and proven to control infectious laryngotracheitis (Vagnozzi et al., 2012). The first type includes vaccines attenuated by multiple passages in embryonated eggs or of chicken embryo origin (CEO). The second type includes vaccines attenuated by multiple passages in tissue culture or of tissue culture origin (TCO). The CEO vaccine has been proven to be effective in producing good protection against the disease (Fulton et al., 2000; Han and Kim, 2003; Rodríguez et al., 2008).

The current study aimed to prepare and evaluate the protection induced by ILTV egg adapted vaccine in SPF chicks. To prepare a live attenuated vaccine master seed virus (MSV), ILTV Fayoum_2018 strain was attenuated by performing five serial passages in embryonated SPF eggs. Testing of the MSV for safety, efficacy and purity was performed, followed by titration in SPF eggs before the preservation of MSV aliquots at -70°C for future use. The virus titer reached 3.5 log₁₀ EID₅₀/ml at the 5th passage. The obtained virus titer by the 5th passage, i.e., 3.5 log₁₀ EID₅₀/ml, come in accordance with the titer recommended by OIE for MSV safety testing (OIE, 2018) and acceptable in comparison to internationally manufactured live attenuated ILT vaccines, LTVAX (ISBI spa, Italy), ILT vac (TAD Pharmazeutishes Werk GmbH, Germany), LaryngovacTM (Solvay Animal Health, Inc., USA), and Laryngo-vac (Intervet International B.V., Netherland), which have 3.0, 3.1, 3.5, 3.2 log EID₅₀/dose virus titer, respectively (Han and Kim, 2003).

The pock lesions of the propagated virus on CAM (Figure 1) appeared typical to ILTV. Evaluation of the prepared vaccine was proven to be sterile (i.e., free from any bacterial, fungal and mycoplasma contaminants and free from extraneous viruses). Also, it was completely safe when inoculated either in the protective dose or in a 10-times-dose showing no adverse effect attributable to the vaccine in agreement with OIE recommendation (OIE, 2014).

Assessment of pathogenicity of the virus isolate used in vaccine preparation was conducted in 3 weeks old SPF chickens by calculating the ITPI. The clinical signs and mortalities exhibited by each bird were scored daily for 14 days. The negative controls exhibited a 0.0 value for ITPI. The virus isolates from each passage (from 2nd till 5th passage) were inoculated intra-tracheal in SPF chicken. However, Fayoum_2018 ILT isolates revealed ITPI values of 0.4, 0.4, 0.1, and 0.0 for 2nd, 3rd, 4th, and 5th, respectively as shown in Table 1) attenuation of the virus by serial passaging in ECE for five times. These results come in accordance with a previous study that mentioned ITPI values of ILT vaccine strains ranging from 0.0 to 0.14 and values of 0.2 to 0.82 for high virulence ILTV strains (Guy et al., 1990). Accordingly, the propagated virus from the 5th passage was used as an MSV for the preparation of the ILT vaccine under test.

Although antibodies to ILTV in chicken serum can be detected by virus neutralization (VN), AGID, and indirect immunofluorescence tests, the ELISA test is very sensitive and possibly the best available test for surveillance of ILTV infection (OIE, 2018). In this study, the assessment of antibodies against ILTV was carried out using a commercial indirect ELISA kit on serum samples collected 2, 3, 4, 5, and 6 weeks post-vaccination. All collected sera of vaccinated chickens showed positive results over the kit’s 611 Positive/negative cut-off point. Moreover, an ascending increase of the antibody titer represented by 1905 absorbance at the 2nd week post-vaccination to 3497 at the 6th week post-vaccination was obtained, indicating that the vaccine built a strong immune response lasting till the 6th week of immunization.

CONCLUSIONS

In conclusion, the attenuated live vaccine prepared at this study using the recently isolated and characterized local ILTV isolate Fayoum_2018 with accession number (MN082684), was safe, pure, potent and also capable to induce a strong immune response till the 6th week post-vaccination and appropriate for its use in mass vaccine production.

REFERENCES


CFR (CODE OF AMERICAN FEDERAL REGULATION-13CFR) USA 2017. Published by the office of the federal register national archives records service, Animals and animal products Ch.111.30-11333.


Nada A. Fathy et al.....


OIE MANUAL .2018.Aavian Infectious Laryngo-tracheitis

OIE TERRESTRIAL MANUAL. 2014. Chapter 2.3.3 Avian Infectious Laryngo-tracheitis


How to cite this article:

DOI: HTTPS://DX.DOI.ORG/10.21608/JAVS.2020.101927